Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Advanced Medical Solutions extends deadline for H.B. Fuller to 2 July
Advanced Medical Solutions has extended the “put up or shut up” deadline for H.B. Fuller to 2 July 2026 at 17:00 London time. The Takeover Panel approved the extension; the original deadline expired today. The parties continue to hold talks, no firm offer has been confirmed, and the AMS board is advising shareholders to take no action for now. » Más en de.investing.com
Advanced Medical Solutions invites shareholders to annual general meeting on 17 June
Advanced Medical Solutions has sent its annual report and financial statements for the year ended 31 December 2025, together with the invitation to the annual general meeting, to shareholders. The AGM will be held on 17 June 2026 at 11:00 in the offices of Investec Bank, 30 Gresham Street, London. The annual report, financial statements and proxy form are available in the investor relations section of the company's website. » Más en de.investing.com
Advanced Medical Solutions: 2025 annual results in line with guidance with strong Surgical growth
Advanced Medical Solutions reported 2025 revenue of £228.9m and adjusted EBITDA of £49.9m (adjusted EBITDA margin 21.8%), in line with the January update and analyst consensus. The Surgical division grew 36% at constant currency and was a major contributor; Woundcare rose 9% at constant currency. Margins were 24.4% (Surgical) and 13.6% (Woundcare); EPS came in 3% below the FactSet consensus due to higher interest expenses. Synergies from the acquisitions of Peters and Syntacoll are progressing as planned, and the company expects 2026 revenue and EBITDA to be in line with market expectations, with strong cash generation to reduce debt. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 134,02 M | - |
| Beneficio bruto | 64,69 M | - |
| Beneficio neto | -75,45 mil | - |
| EBITDA | 30,16 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 732,92 M € |
Número de acciones | 216,4 M |
Máximo/mínimo de 52 semanas | 3,41 € - 2,24 € |
| Dividendos | No |
Beta | 0,75 |
Ratio P/E | 166,18 |
Ratio PEG | -2,78 |
Ratio P/B | 2,41 |
Ratio P/S | 2,62 |
Perfil de la empresa
Advanced Medical Solutions Group plc, junto con sus filiales, diseña, desarrolla, fabrica y distribuye productos para los mercados de cuidado de heridas, cirugía y cierre de heridas en el Reino Unido, Alemania, Francia, el resto de Europa, Estados Unidos e internacionalmente. Opera en dos segmentos, Surgical y Woundcare. El segmento Surgical ofrece adhesivos tópicos para tejidos destinados al cierre y sellado de heridas bajo la marca LiquiBand; suturas y productos a base de colágeno para los mercados quirúrgico y dental bajo la marca RESORBA; colágenos; y un dispositivo laparoscópico utilizado para fijar mallas para hernias colocadas en el interior del cuerpo bajo la marca LiquiBand Fix8, así como selladores internos bajo las marcas Seal-G/Seal-G MIST. El segmento Woundcare proporciona tecnologías de plataforma para el cuidado de heridas, que incluyen alginatos, espumas, películas, fibras, hidrogeles, apósitos antimicrobianos e hidrocoloides, así como productos para el cuidado de heridas bajo la marca ActivHeal. Advanced Medical Solutions Group plc se constituyó en 1991 y tiene su sede en Winsford, Reino Unido.
| Nombre | Advanced Medical Solutions |
| CEO | Andrew Christopher Meredith |
| Sede | Winsford,
ch Reino Unido |
| Sitio web | |
| Salida a bolsa | 16/12/1994 |
| Empleados | 1800 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
London Stock Exchange | AMS.L |
Frankfurt | AQA.F |
Düsseldorf | AQA.DU |
London | AMS.L |